Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Catalent Inc
(NY:
CTLT
)
56.34
+0.38 (+0.68%)
Streaming Delayed Price
Updated: 11:05 AM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Catalent Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
April 12, 2024
BMO's coverage of Novo Nordisk, spotlighting its groundbreaking advancements in weight loss and diabetes drugs. Analysts foresee Novo and Eli Lilly maintaining dominance in the obesity market, fueled...
Via
Benzinga
Beyond The Numbers: 6 Analysts Discuss Catalent Stock
April 04, 2024
Via
Benzinga
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?
March 26, 2024
All three of these high-flying stocks could have more room to run.
Via
The Motley Fool
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
March 23, 2024
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility.
Via
Talk Markets
Did Novo Nordisk Just Get a Jump on Eli Lilly?
March 19, 2024
A recent FDA announcement may have just put one company in the lead.
Via
The Motley Fool
Exposures
Product Safety
(CTLT) - Analyzing Catalent's Short Interest
February 28, 2024
Via
Benzinga
In-Depth Examination Of 5 Analyst Recommendations For Catalent
February 20, 2024
Via
Benzinga
Earnings Outlook For Catalent
February 08, 2024
Via
Benzinga
Why Catalent Stock Soared Today
February 05, 2024
Catalent has agreed to be acquired by Novo Nordisk's parent company.
Via
The Motley Fool
The Top 3 Pharma Stocks to Buy in March2024
March 09, 2024
Investors explore the top three biotechnology stocks to buy in 2024 which are leading the anti-obesity market surge.
Via
InvestorPlace
Novo Nordisk Sets Timeframe For Its Next-Gen Experimental Obesity Drug
March 08, 2024
"Novo Nordisk's optimism soars with promising early trial data for amycretin, an experimental weight loss pill. Expect significant weight loss and cardiovascular benefits. Phase 2 trial begins in late...
Via
Benzinga
Escalating Demand for Obesity Drugs Creates Time-Sensitive Race for Eli Lilly, Novo Nordisk
March 06, 2024
Eli Lilly's strategic collaborations with outsourcing partners for Zepbound (tirzepatide) production. Challenges persist as Eli Lilly and Novo Nordisk address production bottlenecks amid rising...
Via
Benzinga
Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why
March 05, 2024
Eli Lilly and Novo Nordisk dominate the diabetes market thanks to blockbuster medications Mounjaro, Ozempic, and Rybelsus.
Via
The Motley Fool
Record-High S&P 500 Propels SPY ETF To $500-Billion Milestone, Nvidia Tops $2 Trillion, Broadcom Surpasses Tesla
March 01, 2024
U.S. stock market continues bull run, hitting record highs for S&P 500 and Nasdaq 100. SPY ETF surpasses $500 billion AUM, with other companies also reaching milestones.
Via
Benzinga
Topics
ETFs
Stocks
Exposures
US Equities
Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit)
February 29, 2024
Nvidia Corp. is one of the leading top stocks with 60% gain in 2024, but other lesser-known names have outperformed.
Via
Benzinga
Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors
February 26, 2024
Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new obesity drugs and pushing the company's shares 30% higher.
Via
Benzinga
Nearly Half Of S&P 500 Stocks Trade Below 50-Day Moving Average: Which One Is The Cheapest?
February 14, 2024
Nearly half of S&P 500 stocks are below 50-day moving average, indicating poor market breadth. Only top 5 companies shielded from bearish pressures.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Novo Nordisk, Eli Lilly Stride To Boost Supply Shortage For Newly Found Holy Grail Of Miraculous Weight Loss Drugs
February 12, 2024
Challenges and updates in the weight loss drug market, as Novo Nordisk and Eli Lilly address supply shortages for Wegovy and Mounjaro. Strategies to meet the increasing demand and potential market...
Via
Benzinga
Novo Nordisk Is Scaling a Barrier to Growth. Should You Buy Its Stock Now?
February 11, 2024
Even more revenue is on the way from additional sales of Wegovy.
Via
The Motley Fool
Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited
February 10, 2024
Novo Nordisk just made a unique acquisition to help bolster the supply of Wegovy and Ozempic.
Via
The Motley Fool
US Stocks Set To Open Higher, Finish Week Stronger Amid Mixed Earnings: Analyst Sees Another Leg-Up Ahead Of Historically Weak March
February 09, 2024
The upward momentum that has been in play in recent sessions could cushion the market, especially as most major indices are in uncharted territory.
Via
Benzinga
Earnings Scheduled For February 9, 2024
February 09, 2024
Companies Reporting Before The Bell • TELUS (NYSE:TU) is expected to report quarterly earnings at $0.23 per share on revenue of $5.24 billion.
Via
Benzinga
The Skinny On Novo Nordisk: Weight-Loss Meds Make Big Pharma A Big Foe For Food Industry
February 08, 2024
Novo Nordisk's groundbreaking weight-loss treatments are causing concern in the food industry. CEOs are seeking advice from the company.
Via
Benzinga
Catalent's Bloomington Plant Making Novo Nordisk's Obesity Drug Faces FDA Scrutiny Regarding Drug Manufacturing Concerns
February 07, 2024
Novo Nordisk faces manufacturing challenges and drug shortages for diabetes and weight loss drugs, impacting Wegovy and Ozempic.
Via
Benzinga
Exposures
Product Safety
Eli Lilly, Novo Nordisk Could Be First Trillion-Dollar Drug Stocks
February 06, 2024
Thanks to weight loss and obesity drugs, Eli Lilly and Novo Nordisk could become the first trillion-dollar stocks in the pharma industry.
Via
InvestorPlace
Catalent Analysts Raise Their Forecasts Following Acquisition News
February 06, 2024
On Monday, Catalent, Inc. (NYSE: CTLT) announced it will be acquired by Novo Holdings. Novo Holdings will acquire all outstanding shares of Catalent for $63.50 per share in cash.
Via
Benzinga
Uber To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
February 06, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Why Novo Nordisk Stock Crushed the Market on Monday
February 05, 2024
The pharmaceutical giant will receive three manufacturing facilities from its parent company's latest acquisition.
Via
The Motley Fool
Stocks Fall As Traders Dial Back Rate Cut Bets; Dollar, Treasury Yields Rise: What's Driving Markets Monday?
February 05, 2024
Wall Street ends week on negative note as traders revise down expectations on Fed rate cuts. Strong economic data and Fed officials' comments push stocks into red, reducing rate cut expectations for...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Amgen Is Trying To Take On Lilly, Novo In Obesity Treatment — Here's Why Lilly Stock Just Hit A Record
February 05, 2024
Amgen is looking to rival Eli Lilly and Novo Nordisk in weight-loss drugs.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.